The PPARα–leukotriene B4 pathway to inflammation control
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Inflammation is a local immune response to 'foreign' molecules, infection and injury. Leukotriene B4, a potent chemotactic agent that initiates, coordinates, sustains and amplifies the inflammatory response, is shown to be an activating ligand for the transcription factor PPARalpha. Because PPARalpha regulates the oxidative degradation of fatty acids and their derivatives, like this lipid mediator, a feedback mechanism is proposed that controls the duration of an inflammatory response and the clearance of leukotriene B4 in the liver. Thus PPARalpha offers a new route to the development of anti- or pro-inflammatory reagents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FFAs act as PPAR agonists facilitating translocation to the nucleus and dimerization to RXR [77,78].”
From Lipoprotein Lipase Regulates Microglial Lipid Droplet Accumulation (2021) · cites this paper as [77]
In the citing paper
“PPAR-α is involved in the regulation of pro-inflammatory genes, mainly by limiting cytokine expression.[109]”
From Nuclear receptors in liver fibrosis (2021) · cites this paper as [109]
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B., Dahlén, S.-E., Lindgren, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Self-citationKliewer, S. A., Lenhard, J. M., Willson, T. M., Patel, I., Morris, D. C., & Lehmann, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90194-9 · Cited by 2,028
Kliewer, S. A., Umesono, K., Noonan, D. J., Heyman, R. A., & Evans, R. M. (1992) · Nature · doi:10.1038/358771a0 · Cited by 1,741
Lee, S. S.-T., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P. M., Westphal, H., & Gonzalez, F. J. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.6.3012 · Cited by 1,655
Self-citationKliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K., & Evans, R. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7355 · Cited by 1,400
Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors
Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G., & Wahli, W. (1992) · Cell · doi:10.1016/0092-8674(92)90031-7 · Cited by 1,376
Self-citation
Research works printed but not linked: 6
- Ford-Hutchinson, A. W. Crit. Rev. Immunol. 10, 1–11 (1990).
- Desvergne, B. & Wahli, W. in Inducible Transcription Vol. 1 (ed. Bæuerle, P.) 142–176 (Birkhäuser, Boston, 1995).
- Greene, M. E. et al. Gene Expr. 4, 281–299 (1995).
- Schmidt, A. et al. Mol. Endocrinol. 6, 1634–1641 (1992).
- Yu, K. et al. J. Biol. Chem. 270, 23975–23983 (1995). · DOI · Paper page
- Peters, J. M. et al. Mol. Pharmacol. 50, 67–94 (1996).
Cited by
Items 401–500 of 1,001
Bezafibrate is a dual ligand for PPARα and PPARβ: studies using null mice
Peters, J. M., Aoyama, T., Burns, A., & Gonzalez, F. J. (2003) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(03)00065-9 · Cited by 100
Self-citationEnzymes and receptors in the leukotriene cascade
Haeggström, J. Z., & Wetterholm, A. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-002-8463-1 · Cited by 102
Hepatic PPARs: Their Role in Liver Physiology, Fibrosis and Treatment
Zardi, E., Navarini, L., Sambataro, G., Piccinni, P., Sambataro, F., Spina, C., & Dobrina, A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990136 · Cited by 90
RXR Agonists Activate PPARα-Inducible Genes, Lower Triglycerides, and Raise HDL Levels In Vivo
Mukherjee, R., Strasser, J., Jow, L., Hoener, P., Paterniti, J. R., & Heyman, R. A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.2.272 · Cited by 89
Systems biology at the Institute for Systems Biology
Hood, L., Rowen, L., Galas, D. J., & Aitchison, J. D. (2008) · Briefings in Functional Genomics and Proteomics · doi:10.1093/bfgp/eln027 · Cited by 96
Hu, P., Li, K., Peng, X., Kan, Y., Li, H., Zhu, Y., Wang, Z., Li, Z., Liu, H., & Cai, D. (2023) · Nutrients · doi:10.3390/nu15224772 · Cited by 97
Babaev, V. R., Ishiguro, H., Ding, L., Yancey, P. G., Dove, D. E., Kovacs, W. J., Semenkovich, C. F., Fazio, S., & Linton, M. F. (2007) · Circulation · doi:10.1161/circulationaha.106.684704 · Cited by 86
Sex differences in nuclear receptor-regulated liver metabolic pathways
Rando, G., & Wahli, W. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.12.023 · Cited by 100
“In addition, PPARα is a target of hypothalamic hormone signaling; furthermore, it plays an important role in the anti-inflammatory action of glucocorticoids [52].”
BackgroundSelf-citationMurakami, K., Ide, T., Suzuki, M., Mochizuki, T., & Kadowaki, T. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0951 · Cited by 92
Transient Receptor Potential Vanilloid-1 Signaling as a Regulator of Human Sebocyte Biology
Tóth, B. I., Géczy, T., Griger, Z., Dózsa, A., Seltmann, H., Kovács, L., Nagy, L., Zouboulis, C. C., Paus, R., & Bíró, T. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2008.258 · Cited by 90
“With respect to sebocyte biology, PPAR ligands stimulate lipid synthesis both in animal models (Rosenfield et al., 1999) and on cultured human immortalized SZ95 and SEB-1 sebocytes that express distinct PPARs (Chen et al., 2003; Alestas et al., 2006; Trivedi et al., 2006).”
BackgroundInfluentialSagar, D. R., Kendall, D. A., & Chapman, V (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.335 · Cited by 89
“For example, PPARa activation modulates the duration of inflammation induced by leukotriene B4 (LTB4)/arachidonic acid and a direct interaction between PPAR-a and LTB4 increases the catabolism of LTB4, thus providing feedback control of inflammation (Devchand et al., 1996).”
BackgroundGrimaldi, P. A. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7278-5 · Cited by 95
Devine, J. H., Eubank, D. W., Clouthier, D. E., Tontonoz, P., Spiegelman, B. M., Hammer, R. E., & Beale, E. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.19.13604 · Cited by 88
Peroxisome proliferator activated receptor agonists
Kersten, S., & Wahli, W. (2000) · Experientia Supplementum · doi:10.1007/978-3-0348-8393-1_9 · Cited by 89
Self-citationN-3 Polyunsaturated Fatty Acids and Inflammation in Obesity: Local Effect and Systemic Benefit
Wang, Y., & Huang, F. (2015) · BioMed Research International · doi:10.1155/2015/581469 · Cited by 81
“Numerous agonists of the related receptor PPAR have anti-inflammatory activity [125, 126].”
BackgroundEosinophils as a novel cell source of prostaglandin D2: autocrine role in allergic inflammation
Luna-Gomes, T., Magalhães, K. G., Mesquita-Santos, F. P., Bakker-Abreu, I., Samico, R. F., Molinaro, R., Calheiros, A. S., Diaz, B. L., Bozza, P. T., Weller, P. F., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101806 · Cited by 87
Romics, L., Kodys, K., Dolganiuc, A., Graham, L., Velayudham, A., Mandrekar, P., & Szabo, G. (2004) · Hepatology · doi:10.1002/hep.20304 · Cited by 87
Review: Effects of PPAR activation in the placenta and the fetus: Implications in maternal diabetes
Jawerbaum, A., & Capobianco, E. (2010) · Placenta · doi:10.1016/j.placenta.2010.12.002 · Cited by 91
Tugwood, J. D., Holden, P. R., James, N. H., Prince, R. A., & Roberts, R. A. (1998) · Archives of Toxicology · doi:10.1007/s002040050483 · Cited by 87
“A transgenic mouse line that has a homozygous disruption of the PPARa gene shows no hepatic enzyme induction or liver growth in response to PP administration (Lee et al. 1995), and recently evidence has been provided for the direct binding of xenobiotic PPs to PPARa ( Devchand et al. 1996; Dowell et al. 1997).”
BackgroundZhu, C., Solorzano, C., Sahar, S., Realini, N., Fung, E. S., Sassone‐Corsi, P., & Piomelli, D. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.070201 · Cited by 90
“Such a role is consistent with the phenotype of PPAR- -deficient mice, which display a heightened sensitivity to proinflammatory agents (Devchand et al., 1996), and differentiates PEA from lipid mediators that either enhance the inflammatory process (e.g., prostaglandins) (Flower, 2006) or…”
BackgroundMolecular biology of jasmonic acid biosynthesis in plants
León, J., & Sánchez‐Serrano, J. J. (1999) · Plant Physiology and Biochemistry · doi:10.1016/s0981-9428(99)80043-6 · Cited by 86
Boitier, E., Gautier, J.-C., & Roberts, R. (2003) · Comparative Hepatology · doi:10.1186/1476-5926-2-3 · Cited by 85
PPAR-γ ligands modulate effects of LPS in stimulated rat synovial fibroblasts
Simonin, M.-A., Bordji, K., Boyault, S., Bianchi, A., Gouze, E., Bécuwe, P., Dauça, M., Netter, P., & Terlain, B. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2002.282.1.c125 · Cited by 85
Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis
Bazwinsky‐Wutschke, I., Zipprich, A., & Dehghani, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102516 · Cited by 93
PPARα contributes to colonic protection in mice with DSS-induced colitis
Azuma, Y., Nishiyama, K., Matsuo, Y., Kuwamura, M., Morioka, A., Nakajima, H., & Takeuchi, T. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.07.007 · Cited by 90
Napal, L., Marrero, P. F., & Haro, D. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.09.097 · Cited by 85
Cell Biology of the 5-Lipoxygenase Pathway
Peters-Golden, M. L. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.mar4 · Cited by 85
Mandard, S., & Patsouris, D. (2013) · PPAR Research · doi:10.1155/2013/613864 · Cited by 90
“More than a decade ago, as PPARα is the nuclear receptor for the eicosanoid leukotriene B4 but also for the palmitoylethanolamide (the naturally occurring amide of palmitic acid and ethanolamine), a role for this nuclear receptor in modulating inflammation was evoked [11, 120, 121].”
BackgroundInfluentialHicks, A., Monkarsh, S. P., Hoffman, A. F., & Goodnow, R. A. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1909 · Cited by 84
“Thus, it has been suggested that responses to LTB 4 could represent an integration of pro-inflammatory and anti-inflammatory effects, mediated by cell surface and nuclear receptors, respectively [21] .”
BackgroundSkogsberg, J., McMahon, A. D., Karpe, F., Hamsten, A., Packard, C. J., Ehrenborg, E., & Study, O. B. O. T. W. O. S. C. P. (2003) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2003.01236.x · Cited by 84
Ahmed, W., Orasanu, G., Nehra, V., Asatryan, L., Rader, D. J., Ziouzenkova, O., & Plutzky, J. (2006) · Circulation Research · doi:10.1161/01.res.0000205846.46812.be · Cited by 84
The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling
Desvergne, B., Ijpenberg, A., Devchand, P. R., & Wahli, W. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(97)00182-9 · Cited by 83
Self-citationCyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma
Wu, T. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.04.002 · Cited by 95
Fenofibrate treatment in patients with primary biliary cirrhosis
Ohira, H., Sato, Y., Ueno, T., & Sata, M. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05944.x · Cited by 82
Biosynthesis of leukotriene B4
Wan, M., Tang, X. Y., Stsiapanava, A., & Haeggström, J. Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.012 · Cited by 82
Nakamura, M., & Shimizu, T. (2011) · Chemical Reviews · doi:10.1021/cr100392s · Cited by 81
Hou, X., Shen, Y. H., Li, C., Wang, F., Zhang, C., Bu, P., & Zhang, Y. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.043 · Cited by 81
Staumont-Sallé, D., Abboud, G., Brénuchon, C., Kanda, A., Roumier, T., Lavogiez, C., Fleury, S., Rémy, P., Papin, J.-P., Bertrand‐Michel, J., et al. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.12.1165 · Cited by 87
5‐Lipoxygenase Pathway, Dendritic Cells, and Adaptive Immunity
Harizi, H., & Gualde, N. (2004) · BioMed Research International · doi:10.1155/s1110724304310041 · Cited by 102
The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes
Mills, S., Windsor, A. C. J., & Knight, S. C. (2005) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2005.02851.x · Cited by 82
Hill, M. R., Clarke, S., Rodgers, K., Thornhill, B., Peters, J. M., Gonzalez, F. J., & Gimble, J. M. (1999) · Infection and Immunity · doi:10.1128/iai.67.7.3488-3493.1999 · Cited by 81
Self-citationThe Interleukin-1 receptor antagonist is a direct target gene of PPARα in liver
Stienstra, R., Mandard, S., Tan, N. S., Wahli, W., Trautwein, C., Richardson, T. A., Lichtenauer-Kaligis, E. G. R., Kersten, S., & Müller, M. M. (2007) · Journal of Hepatology · doi:10.1016/j.jhep.2006.11.019 · Cited by 86
Self-citationSerrano-Marco, L., Rodríguez-Calvo, R., El Kochairi, I., Palomer, X., Michalik, L., Wahli, W., & Vázquez-Carrera, M. (2011) · Diabetes · doi:10.2337/db10-0704 · Cited by 78
Self-citationControl of adipogenesis by oxylipins, GPCRs and PPARs
Barquissau, V., Ghandour, R. A., Ailhaud, G. P., Klingenspor, M., Langin, D., Amri, E., & Pisani, D. F. (2016) · Biochimie · doi:10.1016/j.biochi.2016.12.012 · Cited by 83
Pang, L., Nie, M., Corbett, L., & Knox, A. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.2.1043 · Cited by 81
“Because PPAR activators enhance COX-2 expression and a large number of NSAIDs have recently been identified as PPAR activators (4, 11), we studied the expression of PPARs in HASM cells.”
BackgroundIntracellular Compartmentalization of Leukotriene Biosynthesis
Peters-Golden, M. L., & Brock, T. G. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.supplement_1.ltta-8 · Cited by 85
Transcriptional Regulation of Hepatic Fatty Acid Metabolism
Guillou, H., Martin, P. G. P., & Pineau, T. (2008) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-1-4020-8831-5_1 · Cited by 90
Hypoxia aggravates non-alcoholic steatohepatitis in mice lacking hepatocellular PTEN
Piguet, A.-C., Stroka, D., Zimmermann, A., & Dufour, J.-F. (2010) · Clinical Science · doi:10.1042/cs20090313 · Cited by 79
Jun, I., Izumi, N., Nishimura, Y., Inoue, K., Ueda, K., Nakanishi, H., Tsuchiya, K., Hamano, K., Asahina, Y., Kurosaki, M., et al. (2004) · Hepatology Research · doi:10.1016/j.hepres.2004.04.001 · Cited by 85
Lipids and the immune response: from molecular mechanisms to clinical applications
Yaqoob, P. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200303000-00002 · Cited by 88
Heng, Y. M., KUO, C.-W. S., Jones, P. S., Savory, R., SCHULZ, R. M., Tomlinson, S. R., Gray, T. J. B., & Bell, D. (1997) · Biochemical Journal · doi:10.1042/bj3250741 · Cited by 79
Endocrinology and immunology of acne: Two sides of the same coin
Zouboulis, C. C. (2020) · Experimental Dermatology · doi:10.1111/exd.14172 · Cited by 66
de Oliveira, A. C. P., Bertollo, C. M., Rocha, L. T. S., Junior, E. B. D. N., Costa, K. A., & Coelho, M. M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.12.026 · Cited by 85
Analgesic, anti-inflammatory, and antipyretic activity
Vogel, H. G., & Vogel, W. H. (1997) · Springer eBooks · doi:10.1007/978-3-662-03333-3_8 · Cited by 84
Maternal low protein diet in rats programmes fatty acid desaturase activities in the offspring
Ozanne, S. E., Martensz, N. D., Petry, C. J., Loizou, C. L., & Hales, C. N. (1998) · Diabetologia · doi:10.1007/s001250051074 · Cited by 78
TRANSCRIPTIONAL ACTIVATION OF CYTOCHROME P450 GENES BY DIFFERENT CLASSES OF CHEMICAL INDUCERS
Dogra, S. C., Whitelaw, M. L., & May, B. K. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02135.x · Cited by 86
Segal, B. H., Kuhns, D. B., Ding, L., Gallin, J. I., & Holland, S. M. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.410 · Cited by 77
“LTB4 is a ligand and activator of peroxisome proliferatoractivated receptors, a group of transcription factors that upregulate expression of hepatic enzymes involved in systemic clearance of LTB4 [ 17 ].”
BackgroundKim, Y.-I., Hirai, S., Goto, T., Ohyane, C., Takahashi, H., Tsugane, T., Konishi, C., Fujii, T., Inai, S., Iijima, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031317 · Cited by 91
“During the past decade, numerous studies have shown that endogenous and naturally occurring biological molecules, including fatty acids and fatty acid-derivatives, serve as PPARα agonists”
BackgroundGene Expression Profiling of the PPAR-alpha Agonist Ciprofibrate in the Cynomolgus Monkey Liver
Cariello, N. F., Romach, E. H., Colton, H. M., Ni, H., Yoon, L., Falls, J. G., Casey, W., Creech, D., Anderson, S. P., Benavides, G. R., et al. (2005) · Toxicological Sciences · doi:10.1093/toxsci/kfi273 · Cited by 77
“a role in the inflammatory response was the demonstration that PPARa agonists increase the degradation of the pro-inflammatory leukotriene B4 (LTB4) (Devchand et al., 1996).”
BackgroundRecent advances in clinical development of leukotriene B4 pathway drugs
Bhatt, L., Roinestad, K., Van, T., & Springman, E. B. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.007 · Cited by 77
Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents.
Kopelovich, L., Fay, J. R., Glazer, R. I., & Crowell, J. A. (2002) · PubMed · Cited by 83
Pathogenesis of alcoholic liver disease: the role of nuclear receptors
Gyamfi, M. A., & Wan, Y. Y. (2010) · Experimental Biology and Medicine · doi:10.1258/ebm.2009.009249 · Cited by 79
Serghides, L., Patel, S. N., Ayi, K., Lu, Z., Gowda, D. C., Liles, W. C., & Kain, K. C. (2009) · The Journal of Infectious Diseases · doi:10.1086/598222 · Cited by 80
Metabolism and signaling activities of nuclear lipids
Fal�, F., Billi, A. M., Cappellini, A., Manzoli, L., Cocco, L., Martelli, A. M., & Faenza, I. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-004-3414-7 · Cited by 81
Han, C. L., Demetris, J. A., Michalopoulos, G. K., Zhan, Q., Shelhamer, J. H., & Wu, T. (2003) · Hepatology · doi:10.1053/jhep.2003.50296 · Cited by 82
Jiang, W. G., Redfern, A., Bryce, R. P., & Mansel, R. E. (2000) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1054/plef.1999.0131 · Cited by 82
Niacin: a re‐emerging pharmaceutical for the treatment of dyslipidaemia
Vosper, H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00349.x · Cited by 81
“Because many inflammatory mediators (such as leukotriene B4) are lipids themselves, PPARa activation also enhances their clearance, and thus plays a major role in limiting the duration of the inflammatory response (Devchand et al., 1996).”
Sveinbjørnsson, B., Rasmuson, A., Baryawno, N., Wan, M., Pettersen, I., Ponthan, F., Orrego, A., Haeggström, J. Z., Johnsen, J. I., & Kogner, P. (2008) · The FASEB Journal · doi:10.1096/fj.07-103457 · Cited by 76
“A third receptor for LTB4 is the nuclear peroxisome proliferator-activated receptor (PPAR-), involved in termination of inflammatory responses ( 51 ).”
BackgroundPeroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise
Sertznig, P., & Reichrath, J. (2011) · Dermato-Endocrinology · doi:10.4161/derm.15025 · Cited by 67
“Sebocytes’ makeup” - Novel mechanisms and concepts in the physiology of the human sebaceous glands
Tóth, B. I., Oláh, A., Szöllősi, A. G., Czifra, G., & Bíró, T. (2011) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-011-0941-6 · Cited by 83
“The differentiation-promoting AA can also stimulate PPARs; likewise, the AA-derivative LTB4 was shown to act as a potent activator of PPARα [ 28 ].”
BackgroundCrisafulli, C., & Cuzzocrea, S. (2009) · Shock · doi:10.1097/shk.0b013e31818bbad6 · Cited by 74
Ribeiro, A., Pontis, S., Mengatto, L., Armirotti, A., Chiurchiù, V., Capurro, V., Fiasella, A., Nuzzi, A., Romeo, E., Moreno‐Sanz, G., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00114 · Cited by 79
Transcriptional control of physiological and pathological processes by the nuclear receptor PPARβ/δ
Tan, N. S., Vázquez‐Carrera, M., Montagner, A., Sng, M. K., Guillou, H., & Wahli, W. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.001 · Cited by 83
Self-citationChristmas, P., Ursino, S. R., Fox, J. W., & Soberman, R. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21191 · Cited by 75
Roberts‐Thomson, S. J. (2000) · Immunology and Cell Biology · doi:10.1046/j.1440-1711.2000.00921.x · Cited by 79
“48 and in inflammation control, because leukotriene B 4 is a PPARa activator”
BackgroundJiao, H., & Zhao, B.-L. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9538 · Cited by 75
“One of the important physiological roles of PPARs is the regulation of inflammatory reaction (Devchand et al., 1996).”
BackgroundBARRERO, M. J., CAMARERO, N., MARRERO, P. F., & HARO, D. (2003) · Biochemical Journal · doi:10.1042/bj20020851 · Cited by 72
Abdelazeim, S. A., Shehata, N. I., Aly, H. F., & Shams, S. G. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-67784-y · Cited by 80
Ahmadi, Z., Hassanshahi, G., Khorramdelazad, H., Zainodini, N., & Koochakzadeh, L. (2016) · Inflammation · doi:10.1007/s10753-016-0303-9 · Cited by 76
Tan, C. K., Zhuang, Y., & Wahli, W. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1280467 · Cited by 70
Self-citationMiyata, K., McCaw, S. E., Meertens, L. M., Patel, H. V., Rachubinski, R. A., & Capone, J. P. (1998) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(98)00196-8 · Cited by 88
Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study
Liberopoulos, E. N., Florentin, M., Elisaf, M. S., Mikhailidis, D. P., & Tsianos, E. (2010) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401004010120 · Cited by 74
Peroxisome proliferator-activated receptors and the metabolic syndrome
Bragt, M. C. E., & Popeijus, H. E. (2007) · Physiology & Behavior · doi:10.1016/j.physbeh.2007.11.053 · Cited by 79
Neuroprotective effects of dehydroepiandrosterone (DHEA) in rat model of Alzheimer's disease.
Aly, H. F., Metwally, F. M., & Ahmed, H. H. (2011) · Acta Biochimica Polonica · doi:10.18388/abp.2011_2218 · Cited by 73
“Activation of PPARα in vivo causes an upregulation of mRNA and protein levels of a number of peroxisomal and non-peroxisomeassociated enzymes and structural proteins, among them the antioxidant enzymes CAT and Cu,Zn-superoxide dismutase, as well as mediators of the glutathione pathway (Devchand et al., 1996).”
BackgroundImportance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma
Gelfand, E. W. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.08.005 · Cited by 73
Barroso, E., Eyre, E., Palomer, X., & Vázquez‐Carrera, M. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.004 · Cited by 72
Effect of Oral Linoleic and γ-Linolenic Acid on Meibomian Gland Dysfunction
Pinna, A., Piccinini, P., & Carta, F. (2007) · Cornea · doi:10.1097/ico.0b013e318033d79b · Cited by 71
“PGE1 possesses several anti-inflammatory properties, including inhibition of superoxide, tumor necrosis factor, interleukin-1b, and interleukin 6.(14) Furthermore, 15-OH-DGLA inhibits 5-lipoxygenase, thus reducing the production of arachidonic acid–derived eicosanoids with proinflammatory properties, such as leukotrie…”
BackgroundInsights into the role of hepatocyte PPARα activity in response to fasting
Régnier, M., Polizzi, A., Lippi, Y., Fouché, E., Michel, G., Lukowicz, C., Smati, S., Marrot, A., Lasserre, F., Naylies, C., et al. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.07.035 · Cited by 72
Self-citationMa, H., Sprecher, H. W., & Kolattukudy, P. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30131 · Cited by 71
Knight, B. L., Patel, D. D., Humphreys, S. M., Wiggins, D., & Gibbons, G. F. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300042-jlr200 · Cited by 71
Garg, M., & Khanna, D. (2014) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944714531638 · Cited by 71
“Fenofibrate confers its benefits on endothelial function, inflammatory cytokines, cardiac hypertrophy and vascular dysfunction by showing increased expression of peroxisome proliferatoractivated receptor-α in ISO-induced acute MI with reduction of cardiac marker enzymes [lactate dehydrogenase (LDH) and creatine phosph…”
MethodPeroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
Han, X., Wu, Y., Yang, Q., & Cao, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107791 · Cited by 75
Role of Human CYP4F2 in Hepatic Catabolism of the Proinflammatory Agent Leukotriene B4
Jin, R., Koop, D. R., Raucy, J. L., & Lasker, J. M. (1998) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.0880 · Cited by 71
Martin, H. L., Mounsey, R. B., Mustafa, S., Sathe, K., & Teismann, P. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.02.017 · Cited by 79
“Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand activated transcription factor with a wide variety of biological roles including control of lipid metabolism and regulation of inflammation (Delerive et al., 2001; Desvergne and Wahli, 1999; Devchand et al., 1996).”
BackgroundAnimal models of nonalcoholic fatty liver disease and steatohepatitis
Nanji, A. A. (2004) · Clinics in Liver Disease · doi:10.1016/j.cld.2004.04.002 · Cited by 75
Thunnissen, M. M. G. M., Andersson, B., Samuelsson, B. O., Wong, C., & Haeggström, J. Z. (2002) · The FASEB Journal · doi:10.1096/fj.01-1017fje · Cited by 71
“... and rate-limiting step in the biosynthesis of LTB4, a potent lipid chemoattractant involved in inflammation (3, 4), immune responses (5), host defense against infection (6, 7), and platelet activating factor (PAF)-induced shock (3, 8). Inasmuch as LTB4 has been shown to act as a natural ligand of the nuclear recep…”
BackgroundPPARs in Inflammation, Atherosclerosis and Thrombosis
Duez, H., Fruchart, J., & Staels, B. (2001) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670100800402 · Cited by 77
Bacterial Lipopolysaccharide Activates HIV Long Terminal Repeat Through Toll-Like Receptor 4
Equils, O., Faure, E., Thomas, L. S., Bulut, Y., Trushin, S., & Arditi, M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.4.2342 · Cited by 76
Leukotrienes: Mediators that have been typecast as villains
Flamand, N., Mancuso, P., Serezani, C. H., & Brock, T. G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7228-2 · Cited by 70
Fang, X., Hu, S., Watanabe, T., Weintraub, N. L., Snyder, G. D., Yao, J., Liu, Y., Shyy, J. Y.-J., Hammock, B. D., & Spector, A. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085605 · Cited by 75
“After 18 h of incubation, Wy-14643 (20 M), a fibric acid derivative that is widely used as a PPAR activator ( Devchand et al., 1996 ), did not increase the PPAR activity in control conditions but caused a 10-fold increase in PPAR activity in cells that overexpressed PPAR.”
Background
Metadata
- Authors
- Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J., & Wahli, W.
- Affiliations
- University of Lausanne (CH)
- National Institutes of Health (US)
- Venue
- Nature
- Published
- 1996-11
- Volume
- 384
- Issue
- 6604
- Pages
- 39-43
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1671834350
- Cited by
- 1,345
- References
- 43
- Citations by year
- 2026: 3 · 2025: 17 · 2024: 14 · 2023: 21 · 2022: 9 · 2021: 38 · 2020: 30 · 2019: 23 · 2018: 21 · 2017: 24 · 2016: 23 · 2015: 22 · 2014: 43 · 2013: 34 · 2012: 49
- FWCI
- 28.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- PPARα, leukotriene B4, inflammation, transcription factor activation, fatty acid oxidation, lipid mediators, chemotaxis, anti-inflammatory agents, liver, feedback regulation
- MeSH terms
- Adaptation, Physiological, Animals, Cells, Cultured, Fatty Acids, Female, Gene Expression Regulation, HeLa Cells, Humans, Inflammation, Leukotriene B4, Ligands, Liver, Male, Oxidation-Reduction, Plasmids, Pyrimidines, Time Factors, Transcription Factors, Transfection, Chloramphenicol O-Acetyltransferase, Arachidonic Acid, Rats, Sprague-Dawley, Receptors, Cytoplasmic and Nuclear, Inflammation Mediators, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.